After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension
European Heart Journal - Cardiovascular Pharmacotherapy
16 May 2024
Organised by: 
Contributors
You may be interested in
Congress Presentation
